Posted by Michael Wonder on 21 Oct 2024
Protara Therapeutics granted FDA fast track designation for intravenous choline chloride for patients receiving parenteral support
21 October 2024 - Remain on track to initiate registrational THRIVE-3 trial in Q1, 2025.
Protara Therapeutics today announced that the US FDA has granted fast track designation to intravenous choline chloride, the Company’s investigational intravenous phospholipid substrate replacement therapy, as a source of choline for adult and adolescent patients on parenteral support for whom oral or enteral nutrition is not possible, insufficient, or contra-indicated.
